Dr Sean Gill and Dr Chetan Mukhtyar (Norfolk and Norwich University Hospital, UK) discuss the efficacy of tocilizumab for GCA, based on a 12-month extension of Stone et al.’s landmark clinical trial. Dr Mukhtyar provides an overview of the trial, including key findings, limitations, and implications for clinical practice.
Read the paper: https://doi.org/10.1093/rheumatology/keab418
Keywords: Giant cell arteritis, GCA, vasculitis, large vessel, tocilizumab, rheumatology, treatment, biologic, biological therapy, IL-6
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
Dr Sean Gill and Dr Chetan Mukhtyar (Norfolk and Norwich University Hospital, UK) discuss the efficacy of tocilizumab for GCA, based on a 12-month extension of Stone et al.’s landmark clinical trial. Dr Mukhtyar provides an overview of the trial, including key findings, limitations, and implications for clinical practice.
Read the paper: https://doi.org/10.1093/rheumatology/keab418
Keywords: Giant cell arteritis, GCA, vasculitis, large vessel, tocilizumab, rheumatology, treatment, biologic, biological therapy, IL-6
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.